Forced degradation study of thiocolchicoside: Characterization of its degradation products

Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche and Drug and Food Biotechnology Centre, Università degli Studi del Piemonte Orientale Amedeo Avogadro, Largo Donegani 2, 28100 Novara, Italy.
Journal of pharmaceutical and biomedical analysis (Impact Factor: 2.98). 03/2012; 61:215-23. DOI: 10.1016/j.jpba.2011.12.008
Source: PubMed


Thiocolchicoside (TCC, N-[1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide) was subjected to hydrolytic, oxidative, and photolytic stresses. TCC underwent degradation in acidic, basic, and oxidative conditions, while it was stable toward other stress conditions. The degradation products (DPs) were detected and their separation was achieved on a SGE Wakosil C18RS 5μm (250*4.6 mm; SGE) column employing a gradient LC-MS method for a total time of analysis of 18 min. The mass fragmentation pathways of both thiocolchicoside and its degradation products were established using LC-MS experiments assigning the structures to the DPs. In particular, five DPs were identified as: D1SO (N-[1,2-dimethoxy-10-methylsulphoxide-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D1SO(2) (N-[1,2-dimethoxy-10-methylsulphone-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide), D2 ([1,2-dimethoxy-10-methylsulphanyl-9-oxo-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-yloxy)-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine), D3 (N-[1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide or 3-O-demethylthiocolchicine), D4 ([1,2-dimethoxy-3-hydroxy-10-methylsulphanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amine or N-deacetyl-3-O-demethylthiocochicine). Moreover, the structures of DPs were confirmed by synthesis of the reference standards which were fully characterized by MS, NMR, IR analyses. Finally a comprehensive degradation scheme of TCC was proposed allowing to outline D1SO and D3 as the indicators of its stability for oxidative and hydrolytic stress conditions.

Download full-text


Available from: Giorgio Grosa,
  • Source
    • "Some analytical methods, such as LC-ESI-MS [5] RP- HPLC [6] [7] and UV-Spectrophotometric [8] [9] have been established for the determination of thiocolchicoside alone in bulk and pharmaceutical formulations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A new stability-indicating reversed-phase high-performance thin-layer chromatographic (RP-HPTLC) method for densitometric analysis of thiocolchicoside was developed and validated. The chromatograms were developed using aluminum plates pre-coated with silica gel 60 RP-18 F254S as a stationary phase and methanol : water (70 : 30 v/v) as a mobile phase. The compact band for thiocolchicoside was observed at R f value of 0.60 ± 0.02 at an absorption wavelength of 377 nm. The linear regression data for the calibration plots (r (2) = 0.9984) was found with respect to peak area in the concentration range of 100-600 ng per band. The limit of detection (LOD) and limit of quantification (LOQ) were 9.77 ng and 29.63 ng, respectively. The drug was exposed to acidic and alkaline hydrolysis, oxidation, photo degradation, and dry heat conditions. The peaks of degradation products were well-resolved from the peak of the standard drug with significantly different R f values. Statistical analysis proved that the established RP-HPTLC method is reproducible, selective, and accurate for the determination of thiocolchicoside in its formulations. The method can effectively separate the drug from its degradation products, and it can be considered as stability-indicating assay.
    Journal of Analytical Methods in Chemistry 09/2013; 2013:142628. DOI:10.1155/2013/142628 · 0.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review describes an epigrammatic impression of the recent trends in analytical perspectives of degradation and impurities profiling of pharmaceuticals including active pharmaceutical ingredient (API) as well as drug products during 2008-2012. These recent trends in forced degradation and impurity profiling were discussed on the head of year of publication; columns, matrix (API and dosage forms) and type of elution in chromatography (isocratic and gradient); therapeutic categories of the drug which were used for analysis. It focuses distinctly on comprehensive update of various analytical methods including hyphenated techniques for the identification and quantification of thresholds of impurities and degradants in different pharmaceutical matrices.
    Journal of pharmaceutical and biomedical analysis 07/2013; 86C:11-35. DOI:10.1016/j.jpba.2013.07.013 · 2.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A forced degradation study is an essential step in the design of a regulatory compliant stability program for both drug substances and products, and was formalized as a regulatory requirement in ICH Guideline Q1A in 1993. It has since been extended to generic drugs. We provide an update on world-wide regulatory requirements. Also, we list all possible benefits of forced degradation studies to assess the stability of drugs and products. We discuss the kind of forced degradation study likely to meet regulatory expectations. We include the knowledge gained from these studies within the Quality by Design paradigm.
    TrAC Trends in Analytical Chemistry 09/2013; 49:71–88. DOI:10.1016/j.trac.2013.05.006 · 6.47 Impact Factor
Show more